STING-targeted PET imaging: unveiling tumor immunogenicity post-chemotherapy in colorectal cancer.
A study published in the European Journal of Nuclear Medicine & Molecular Imaging explores the potential of STING-targeted PET imaging in monitoring tumor immunogenicity in colorectal cancer (CRC) patients after chemotherapy. The study uses a novel PET tracer called [18F]FBTA, which demonstrates hig...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 9; pp. 2758 - 2761 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | A study published in the European Journal of Nuclear Medicine & Molecular Imaging explores the potential of STING-targeted PET imaging in monitoring tumor immunogenicity in colorectal cancer (CRC) patients after chemotherapy. The study uses a novel PET tracer called [18F]FBTA, which demonstrates higher specificity and sensitivity compared to conventional [18F]FDG. The research findings indicate that [18F]FBTA accurately reflects the impact of different chemotherapeutic agents on the immune activity of CRC tumors. The study suggests that [18F]FBTA holds promise as a reliable clinical tool for guiding treatment decisions and facilitating the combination of immunotherapy with chemotherapy in CRC patients. |
|---|